Table 4.

Small molecules with HDAC-inhibiting activity.

HDAC inhibitor	Target	Disease	Fibrosis-related output	Status	Ref.
HNHA	Pan	Tumor	Improves hepatic function survival	FDA approval	159
Vorinostat	Pan	Cutaneous T-cell lymphoma, glioma	Inhibits TGF-β/SMAD signaling	FDA approve	160
VPA	Class I HDACs	Epilepsies, Partial	Inhibits TGF-β and TNF-α signaling	FDA approve	161
Entinostat	Class I HDACs	Breast cancer, lymphoma	Inhibits hepatocyte death and type 2 inflammation	III clinical trial	162
BRD4884	Class I HDACs	Memory disorders	Inhibits hepatocyte death and type 2 inflammation	Pre-clinical	162
NW21	Class I HDACs	Hematologic neoplasms, solid tumors	Inhibits hepatocyte death and type 2 inflammation	Drug discovery	162
Largazole	Pan	Tumor	Inhibits VEGF signaling	Drug discovery	163
Parthenolide	HDAC4	Tumor	Downregulates TGF-β and upregulates CYP7A1	Drug discovery	164
Valproate	Pan	Epilepsies	Inhibits HSC activation	Drug discovery	165
MC1568	HDAC4/5/6	Tumor	Inhibits HSC activation	Drug discovery	166